CHONGQING CARELIFE PHARMACEUTICAL CO LTD

Overview

CHONGQING CARELIFE PHARMACEUTICAL CO LTD is an active pharmaceutical ingredient (API) supplier with 76 active FDA Type II Drug Master Files, covering ACITRETIN; ACRIVASTINE; AZACITIDINE USP; AZTREONAM; BENDAMUSTINE HCI MONOHYDRATE; BENDAMUSTINE HCL.

API / Drug Master Files

CHONGQING CARELIFE PHARMACEUTICAL CO LTD holds 76 active (86 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• LURBINECTEDINActive2026-03-31
• CABOTEGRAVIR, NON-STERILE BULK DRUG SUBSTANCEActive2026-01-21
• MITOXANTRONE HYDROCHLORIDEActive2025-12-11
• PEMETREXED DISODIUM HEPTAHYDRATEActive2025-11-05
• SAPROPTERIN DIHYDROCHLORIDEActive2025-07-17
• NUSINERSEN SODIUM, NON-STERILE BULK DRUG SUBSTANCEActive2025-07-07
• SEMAGLUTIDEActive2025-06-23
• IXAZOMIB CITRATE DRUG SUBSTANCEActive2025-05-19
• CARFILZOMIBActive2025-03-11
• CARFILZOMIBActive2025-01-23
• FINERENONE, NON-STERILE BULK DRUG SUBSTANCEActive2024-12-06
• DOLUTEGRAVIR SODIUMActive2024-09-05
• TIRBANIBULINActive2024-03-19
• DACOMITINIBActive2023-11-24
• TENOFOVIR ALAFENAMIDE FUMARATE, NON-STERILE BULK DRUG SUBSTANCEActive2023-11-10

Showing 15 of 86 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to CHONGQING CARELIFE PHARMACEUTICAL CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.